+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


2019 Future of Encephalopathy R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749275
  • Report
  • February 2019
  • Region: Global
  • 60 pages
  • VPA Research
1 of 3


  • AlfaSigma SpA
  • Celgene Corp
  • Cosmo Pharmaceuticals NV
  • GW Pharmaceuticals Plc
  • Knopp Biosciences LLC
  • Mithra Pharmaceuticals SA
  • MORE
The global demand for Encephalopathy treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Encephalopathy pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Encephalopathy pipeline companies from advancing their products into Phase 3 or Phase 4.

Encephalopathy Report Description

The 2019 pipeline study on Encephalopathy pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Encephalopathy pipeline compounds.

The Encephalopathy pipeline guide presents information on all active drugs currently being developed for Encephalopathy. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Encephalopathy pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Encephalopathy drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Encephalopathy product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Encephalopathy pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Encephalopathy pipeline report includes
  • An overview of Encephalopathy disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Encephalopathy pipeline
  • Company wise list of Encephalopathy pipeline
  • Mechanism of Action wise Encephalopathy pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Encephalopathy pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Encephalopathy pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Encephalopathy pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3


  • AlfaSigma SpA
  • Celgene Corp
  • Cosmo Pharmaceuticals NV
  • GW Pharmaceuticals Plc
  • Knopp Biosciences LLC
  • Mithra Pharmaceuticals SA
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Encephalopathy Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Encephalopathy Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Encephalopathy pipeline, H1- 2019
3.5 Mechanism of Action wise Encephalopathy Pipeline Candidates

4 AlfaSigma SpA Encephalopathy Pipeline Details
4.1 AlfaSigma SpA Business Profile
4.2 AlfaSigma SpA Encephalopathy Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 BrainRepair UG Encephalopathy Pipeline Details
5.1 BrainRepair UG Business Profile
5.2 BrainRepair UG Encephalopathy Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Celgene Corp Encephalopathy Pipeline Details
6.1 Celgene Corp Business Profile
6.2 Celgene Corp Encephalopathy Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Chiesi Farmaceutici SpA Encephalopathy Pipeline Details
7.1 Chiesi Farmaceutici SpA Business Profile
7.2 Chiesi Farmaceutici SpA Encephalopathy Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Cosmo Pharmaceuticals NV Encephalopathy Pipeline Details
8.1 Cosmo Pharmaceuticals NV Business Profile
8.2 Cosmo Pharmaceuticals NV Encephalopathy Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Ferring International Center SA Encephalopathy Pipeline Details
9.1 Ferring International Center SA Business Profile
9.2 Ferring International Center SA Encephalopathy Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Gilead Sciences Inc Encephalopathy Pipeline Details
10.1 Gilead Sciences Inc Business Profile
10.2 Gilead Sciences Inc Encephalopathy Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 GW Pharmaceuticals Plc Encephalopathy Pipeline Details
11.1 GW Pharmaceuticals Plc Business Profile
11.2 GW Pharmaceuticals Plc Encephalopathy Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 KannaLife Sciences Inc Encephalopathy Pipeline Details
12.1 KannaLife Sciences Inc Business Profile
12.2 KannaLife Sciences Inc Encephalopathy Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Knopp Biosciences LLC Encephalopathy Pipeline Details
13.1 Knopp Biosciences LLC Business Profile
13.2 Knopp Biosciences LLC Encephalopathy Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 MallInckrodt Plc Encephalopathy Pipeline Details
14.1 MallInckrodt Plc Business Profile
14.2 MallInckrodt Plc Encephalopathy Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 Marinus Pharmaceuticals Inc Encephalopathy Pipeline Details
15.1 Marinus Pharmaceuticals Inc Business Profile
15.2 Marinus Pharmaceuticals Inc Encephalopathy Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 Mithra Pharmaceuticals SA Encephalopathy Pipeline Details
16.1 Mithra Pharmaceuticals SA Business Profile
16.2 Mithra Pharmaceuticals SA Encephalopathy Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 Pairnomix LLC Encephalopathy Pipeline Details
17.1 Pairnomix LLC Business Profile
17.2 Pairnomix LLC Encephalopathy Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 ProThera Biologics Inc Encephalopathy Pipeline Details
18.1 ProThera Biologics Inc Business Profile
18.2 ProThera Biologics Inc Encephalopathy Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 SciFluor Life Sciences LLC Encephalopathy Pipeline Details
19.1 SciFluor Life Sciences LLC Business Profile
19.2 SciFluor Life Sciences LLC Encephalopathy Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 Spherium Biomed SL Encephalopathy Pipeline Details
20.1 Spherium Biomed SL Business Profile
20.2 Spherium Biomed SL Encephalopathy Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 Synlogic Inc Encephalopathy Pipeline Details
21.1 Synlogic Inc Business Profile
21.2 Synlogic Inc Encephalopathy Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 Takeda Pharmaceutical Co Ltd Encephalopathy Pipeline Details
22.1 Takeda Pharmaceutical Co Ltd Business Profile
22.2 Takeda Pharmaceutical Co Ltd Encephalopathy Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 Therapicon Srl Encephalopathy Pipeline Details
23.1 Therapicon Srl Business Profile
23.2 Therapicon Srl Encephalopathy Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24 Umecrine Cognition AB Encephalopathy Pipeline Details
24.1 Umecrine Cognition AB Business Profile
24.2 Umecrine Cognition AB Encephalopathy Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25 Zynerba Pharmaceuticals Inc Encephalopathy Pipeline Details
25.1 Zynerba Pharmaceuticals Inc Business Profile
25.2 Zynerba Pharmaceuticals Inc Encephalopathy Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26. Latest Encephalopathy Drug Pipeline Developments, 2019

27. Appendix
27.1 About Us
27.2 Sources and Methodology
27.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • AlfaSigma SpA
  • BrainRepair UG
  • Celgene Corp
  • Chiesi Farmaceutici SpA
  • Cosmo Pharmaceuticals NV
  • Ferring International Center SA
  • Gilead Sciences Inc
  • GW Pharmaceuticals Plc
  • KannaLife Sciences Inc
  • Knopp Biosciences LLC
  • MallInckrodt Plc
  • Marinus Pharmaceuticals Inc
  • Mithra Pharmaceuticals SA
  • Pairnomix LLC
  • ProThera Biologics Inc
  • SciFluor Life Sciences LLC
  • Spherium Biomed SL
  • Synlogic Inc
  • Takeda Pharmaceutical Co Ltd
  • Therapicon Srl
  • Umecrine Cognition AB
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown